Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
John Danesh a Clinical Trial
Service Unit and Epidemiological Studies Unit, University of Oxford,
Radcliffe Infirmary, Oxford OX2 6HE, b Department of Public Health
Sciences, St George's Hospital Medical School, London SW17 0RE, c Departments of
Medicine and Population Sciences and Primary Care, Royal Free and
University College Medical School, London NW3 2PF, d Imperial
Cancer Research Fund Cancer Epidemiology Unit, Oxford OX2 6HE
Correspondence to:
J Danesh
| |
Abstract |
|---|
|
|
|---|
Objective:
To assess associations between baseline
values of four different circulating markers of inflammation and future risk of coronary heart disease, potential triggers of systemic inflammation (such as persistent infection), and other markers of inflammation.
Circulating concentrations of C reactive protein, serum amyloid A
protein, and serum albumin and the leucocyte count can fluctuate widely
during acute responses to tissue damage or infection. Plasma concentrations of C reactive protein and serum amyloid A protein can
each rise 10 000-fold; the leucocyte count can increase about threefold; and the concentration of serum albumin can fall by about
20%.
1 2
In recent years these "acute phase
reactants" have been studied as potential markers of more subtle and
persistent systemic alterations that may be loosely called low grade
inflammation. If the sharp short term fluctuations are ignored, then
long term circulating concentrations of these factors show a similar
year-to-year consistency within individuals to levels of some more
extensively studied risk factors such as blood cholesterol
concentration and blood pressure.
2 3
Moreover, highly
sensitive assays for C reactive protein and serum amyloid A protein are
now available that can detect low grade inflammation that would
previously have been unnoticed.
4 5
Several reports have suggested that plasma C reactive protein and other
possible markers of low grade inflammation can predict increased risks
of coronary heart disease, but it is not known whether the associations
are causal.
2 6
A variety of mechanisms by which C
reactive protein might directly promote vascular disease have been
proposed,7 but none is proved. These markers of
inflammation might, however, be indicators of chronic infective
processes possibly correlated with risk of coronary heart disease, such
as infection by Chlamydia pneumoniae or chronic gastric
infection with Helicobacter pylori.8
Alternatively, the markers might be mainly indicators of classic
vascular risk factors (such as smoking and obesity) or of the extent of
pre-existing disease (since atherosclerosis may be partly an
inflammatory lesion6). If so, the markers themselves would
not be of causal relevance to disease. Long term prospective studies
with data collected on many possible confounders or mediators can help
to distinguish among these different possibilities since this approach
is generally less influenced than retrospective studies by any effect
of pre-existing disease itself on the factors being
investigated.9
We report one of the largest and most prolonged prospective studies of
"inflammatory" factors and coronary heart disease so far, with
updated meta-analyses of previous relevant studies to put our findings
in context. We measured four circulating markers of inflammation (C
reactive protein, serum amyloid A protein, leucocyte count, and
albumin10), which should help to determine whether there
is some underlying process related to inflammation (rather than any one
marker by itself) that might be relevant to disease. Most previous
studies could not make such assessments because they typically reported
on only one marker of inflammation.
Cases and controls
Design:
Nested case-control comparisons in a
prospective, population based cohort.
Setting:
General practices in 18 towns in Britain.
Participants:
506 men who died from coronary heart
disease or had a non-fatal myocardial infarction and 1025 men who
remained free of such disease until 1996 selected from 5661 men aged
40-59 years who provided blood samples in 1978-1980.
Main outcome measures:
Plasma concentrations of C
reactive protein, serum amyloid A protein, and serum albumin and
leucocyte count. Information on fatal and non-fatal coronary heart
disease was obtained from medical records and death certificates.
Results:
Compared with men in the bottom third of
baseline measurements of C reactive protein, men in the top third had
an odds ratio for coronary heart disease of 2.13 (95% confidence interval 1.38 to 3.28) after age, town, smoking, vascular risk factors,
and indicators of socioeconomic status were adjusted for. Similar
adjusted odds ratios were 1.65 (1.07 to 2.55) for serum amyloid A
protein; 1.12 (0.71 to 1.77) for leucocyte count; and 0.67 (0.43 to
1.04) for albumin. No strong associations were observed of these
factors with Helicobacter pylori seropositivity, Chlamydia pneumoniae IgG titres, or plasma total
homocysteine concentrations. Baseline values of the acute phase
reactants were significantly associated with one another (P<0.0001),
although the association between low serum albumin concentration and
leucocyte count was weaker (P=0.08).
Conclusion:
In the context of results from other
relevant studies these findings suggest that some inflammatory
processes, unrelated to the chronic infections studied here, are likely
to be involved in coronary heart disease.
![]()
Introduction
Top
Abstract
Introduction
Methods
Results
Discussion
References
![]()
Methods
Top
Abstract
Introduction
Methods
Results
Discussion
References
During 1978-80, 7735 men aged 40-59 (response rate 78%) were
randomly selected from general practice registers in each of 24 British
towns. Nurses administered questionnaires, made physical measurements,
recorded an electrocardiogram, and, for 5661 men in 18 of the towns,
collected non-fasting venous blood samples, which were stored at
20°C for subsequent analysis.11 Additional
questionnaires on car ownership and childhood social circumstances
(father's social class and childhood household amenities) were posted
to participants five years (98% response among survivors) and 12 years
(90% response among survivors) after entry.
Laboratory methods
Laboratory workers blind to the case-control status of
participants measured concentrations of C reactive protein and serum
amyloid A protein using sensitive enzyme immunoassays.
4 5
The C reactive protein assay was standardised on the WHO international reference standard, and the results of the serum amyloid A protein assay were used to establish the WHO international reference standard for this protein.14 Albumin was measured with bromocresol
green, and leucocyte counts were done with Coulter counters at the time of blood collection.11 The coefficients of variation
within each of these assays was 2-4%; the variation between the assays was about 6-8%. Measurements were also made of concentrations of serum
IgG antibodies to Helicobacter pylori (by enzyme linked immunoassay, Meridian Diagnostics, Cincinatti, Ohio), IgG antibodies to
Chlamydia pneumoniae (whole organism antigen by time
resolved fluorimetry15) and serum lipids, plasma
homocysteine, glucose, insulin, and markers of renal function (by
standard assays11).
Statistical methods
Case-control comparisons were made by unmatched stratified
logistic regression fitted by unconditional maximum likelihood (Stata
Corporation, Texas, USA). Analysis of concentrations of C reactive
protein, serum amyloid A, and albumin and of leucocyte count was
prespecified to be by thirds of values in the controls. Adjustment was
made for age; cigarette smoking (never, former, current); daily
cigarette consumption; non-fasting blood concentrations of total
cholesterol, high density lipoprotein cholesterol, and triglycerides;
current social class (registrar general's 1980 classification with
separate category for armed forces11); housing tenure
(owner, private rent, council rent); marital status; current car
ownership; and father's occupation (manual, non-manual), family car
ownership, bathroom in house, hot water tap in house, and bedroom
sharing. H pylori seropositivity, C pneumoniae
IgG titres, and concentrations of non-fasting blood lipids, plasma
homocysteine, and other blood components were investigated as possible
correlates of levels of each of the acute phase reactants.
2 tests.
Odds ratios are given with 95% confidence limits, and two sided
probability values are used.
| |
Results |
|---|
|
|
|---|
The mean age at coronary heart disease event among cases was 62 years (mean duration of follow up 9.5 years). There were highly significant differences between cases and controls with respect to known vascular risk factors such as smoking, obesity, blood pressure, and blood lipids concentrations (table 1).
|
Associations among different acute phase reactants
In controls without evidence of coronary heart disease at
baseline, the correlation coefficients of the associations between
plasma C reactive protein and serum amyloid A protein, leucocyte count,
and albumin were 0.58, 0.33, and
0.19 respectively (P<0.0001 for
each), and the correlation coefficients between serum amyloid A protein
and leucocyte count and albumin were 0.19 and 0.14 respectively
(P<0.0001 for each). These associations among the four acute phase
reactants were not adjusted for values of one another to avoid
overadjustment since they may reflect a common underlying process (see
tables on BMJ 's website). Leucocyte count and
serum albumin concentration were not strongly related (R=
0.06, P=0.08).
Acute phase reactants, classic vascular risk factors, and other
characteristics
C reactive protein concentration was strongly associated with
cigarette smoking, body mass index, and low forced expiratory volume in
one second (P<0.0001 for each), and the associations were little
changed by adjustments for age, town, smoking, and indicators of
socioeconomic status. Associations of C reactive protein with high
density lipoprotein cholesterol, triglyceride, urate, and insulin,
however, weakened substantially after such adjustments (table A on
BMJ 's website). There were strong and highly
significant associations of serum amyloid A protein with body mass
index and total cholesterol (P<0.0001) and with low forced expiratory
volume (P<0.001) which remained significant after adjustment for
possible confounders, but such adjustment substantially weakened the
association with high density lipoprotein cholesterol (table B on
website). Strong adjusted associations were observed between leucocyte
count and cigarette smoking and packed cell volume (P<0.0001 for each,
table C on website) and between low albumin and age and cigarette
smoking (P<0.0001 for each, table D on website) and between albumin
and blood pressure, total cholesterol, and packed cell volume
(P<0.0001 for each). Possible associations existed between albumin and
high density lipoprotein cholesterol, triglycerides, and serum markers
of renal function. No consistent associations were observed of these
acute phase proteins with H pylori seropositivity, C
pneumoniae IgG titres, plasma total homocysteine concentrations,
or a range of childhood or adult indicators of socioeconomic status.
|
Acute phase reactants and incident coronary heart disease
The odds ratio for coronary heart disease was 3.46 (95%
confidence interval 2.59 to 4.62;
2 =71, df=1)
in men in the top third compared with those in the bottom third of
baseline C reactive protein concentration (tertile cut offs, >2.4
v <0.9 mg/l). The odds ratio fell to 2.13 (1.38 to
3.28;
2 =11.8, df=1) after smoking, vascular risk
factors, and indicators of socioeconomic status were adjusted for
(table 2). Comparisons between the top and bottom thirds of the other
factors gave the following adjusted odds ratios for coronary heart
disease: 1.65 (1.07 to 2.55) for serum amyloid A protein (>9
v <6 mg/l); 1.12 (0.71 to 1.77) for leucocyte count (>7.8
v 6.4×109/l); and 0.67 (0.43 to 1.04)
for albumin (>46 v <44 g/l). These results were not
materially changed in analyses restricted to the 329 cases and 820 controls with no evidence of coronary heart disease at baseline (table
2) or in analyses restricted to the 227 cases and 779 controls who had
complete information on childhood socioeconomic status. The findings
were also unaffected by varying the prespecified cut-off levels for
analysis of each factor.
| |
Discussion |
|---|
|
|
|---|
Our prospective study in the general British male population shows that baseline values of four acute phase reactants are associated with one another as well as with future risk of coronary heart disease. These data support the idea that there are some underlying processes related to inflammation that are relevant to coronary heart disease. To determine what factor(s) might be triggering such low grade inflammation years in advance of disease, we studied classic risk factors, plasma homocysteine concentration, serological evidence of chronic infection with C pneumoniae or H pylori, and a range of possible other triggers. None, however, was strongly related to inflammatory markers, suggesting that these factors cannot fully account for the associations observed with coronary heart disease. Even though the strength of the association of coronary heart disease with baseline concentrations of C reactive protein and serum amyloid A protein seems comparable with that for some more extensively studied risk factors (such as blood fibrinogen concentration2), several uncertainties remain. We discuss below the strengths and limitations of the available evidence on coronary heart disease and each of these factors in the context of updated meta-analyses of other relevant studies.
C reactive protein
A previous meta-analysis of seven prospective studies of C
reactive protein, with a total of 1053 cases, indicated a risk ratio
for coronary heart disease of 1.7 (95% confidence interval 1.4 to 2.1)
in individuals in the top third compared with those in the bottom third
of baseline measurements.2 Since the publication of that
review, six additional prospective studies of C reactive protein have
been identified, including an additional 994 cases of non-fatal
myocardial infarction or death from coronary heart
disease.17-22 All used sensitive assays and adjusted for smoking and some standard vascular risk factors. In aggregate, the 14 available prospective reports (including the present study of 506 cases) include 2557 cases with a weighted mean age at entry of 58 and
weighted mean follow up of eight years.17-28 There was no
significant heterogeneity among them (
2=6.9, df=13;
P>0.1), and a comparison of individuals with C reactive protein
concentrations in the top third with those in the bottom third at
baseline gave a combined risk ratio of 1.9 for coronary heart disease
(1.5 to 2.3; fig 1) with a similar risk ratio of 2.0 (1.6 to 2.5) in
the 11 studies of the general population (test for heterogeneity,
2=5.8, df=10; P>0.1). The estimated mean usual log
C reactive protein values in the top third and bottom thirds were 0.38 and 0.02 mg/l in the general population, which correspond to mean
estimated usual values of 2.4 and 1.0 mg/l. Hence, this updated
meta-analysis indicates a similar risk ratio to the previous review,
but the scope for the play of chance is now substantially reduced
because there are more than twice as many cases
reported.
|
for example, we did not measure blood fibrinogen
concentration. Secondly, although experimental studies suggest that C
reactive protein might directly contribute to vascular damage (such as
its frequent detection in atherosclerotic plaques,29 its
ability to stimulate tissue factor production by
macrophages,30 and its enhancement of complement
activation after binding partly degraded, non-oxidised low density
lipoprotein cholesterol
31 32
), no direct evidence exists
for such involvement.7 Additional studies are also needed
to determine the relevance of apparently sustained falls in C reactive
protein concentrations after the use of lipid lowering statin
drugs3 as well as apparently sustained increases after
postmenopausal hormone replacement therapy.33
Serum amyloid A protein
Only three previous studies have reported on serum amyloid A
protein and incident coronary heart disease,
22 28 34
including two cohorts defined on the basis of pre-existing coronary heart disease. They comprised 551 cases in total (fig 2). Our 506 cases
in the general population almost double the available evidence. In
aggregate, these four studies include 1057 cases, with a weighted mean
age at entry of 56 and weighted mean follow up of 10 years. There was
no significant heterogeneity among them (
2=0.3,
df=3; P>0.1), and a comparison of individuals with values in the top
third with those in the bottom third at baseline gave a combined risk
ratio of 1.6 for coronary heart disease (1.1 to 2.2; fig 2). The
estimated mean usual log values in these groups were 1.00 and 0.68 mg/l, which correspond to mean values of 10.0 and 4.7 mg/l. Further
studies are needed to determine whether this association is independent
of possible confounders.
|
Leucocyte count and serum albumin
The adjusted odds ratio for coronary heart disease in our study
was 1.12 (0.71 to 1.77) in men with leucocyte counts in the top third
compared with those in the bottom third of baseline measurements.
Although this odds ratio is not significant, it is consistent with a
combined risk ratio for coronary heart disease of 1.4 (1.3 to 1.5)
reported in a previous meta-analysis of 19 prospective studies of
leucocyte count including a total of 7229 cases, with top and bottom
thirds corresponding to mean usual leucocyte counts of 8.4 and
5.6×109/l, respectively.2 We also
observed an adjusted odds ratio for coronary heart disease of 0.67 (0.43 to 1.04) in men in the top third compared with those in the
bottom third of baseline albumin measurements. Again, despite a lack of
conventional significance, this odds ratio is compatible with a
combined risk ratio of 0.7 (0.6 to 0.8) reported in a meta-analysis of
eight prospective studies including a total of 3770 cases, with top and
bottom thirds corresponding to mean usual albumin concentrations of 42 and 38 g/l, respectively.2 The strongly positive
associations of serum albumin values with blood pressure and serum
lipid concentrations indicate that these variables cannot account for
the association between low serum albumin and coronary heart
disease
rather the reverse in fact.
|
What is already known on this topic
Plasma concentrations of C reactive protein and other sensitive markers of systemic inflammation may be correlated with future risk of coronary heart disease in the general population It is not known whether these associations are causal or merely due to confounding by classic risk factors, chronic infective processes, or early disease What this study addsBaseline values of C reactive protein, serum amyloid A protein, leucocyte count, and serum albumin were associated with one another as well as with future risk of coronary heart disease Values of these factors were not associated with markers of chronic infective processes These findings suggest that low grade inflammatory processes may be relevant to coronary heart disease |
Conclusions
We found that baseline levels of four circulating markers of low
grade inflammation were associated with one another and with future
risk of coronary heart disease. The markers, however, were not
associated with some chronic infective processes possibly related to
coronary heart disease. These findings
in the context of results from
other relevant studies
suggest that low grade inflammatory processes
may be relevant to coronary heart disease.
| |
Acknowledgments |
|---|
We thank H Refsum and P Ueland for the homocysteine assays; M Thomas, Yuk-ki Wong and M Ward for C pneumoniae serology; J Atherton and C Hawkey for H pylori serology; and J John for valuable help. Professor AG Shaper established the British Regional Heart Study
Contributors: The study was designed and conducted by the British Regional Heart Study collaborative group. All the named authors contributed to the analysis and interpretation of these data and to writing the paper. JD and PW are the guarantors.
| |
Footnotes |
|---|
Funding: The British Regional Heart Study is a British Heart Foundation research group and also receives support from the Department of Health. JD is supported by Merton College and the Frohlich Trust. MBP is supported by the UK Medical Research Council.
Competing interests: None declared.
Tables showing distribution of
risk factors in the control population are available on the BMJ's
website
| |
References |
|---|
|
|
|---|
| 1. | Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive and related proteins (pentaxins) and serum amyloid A protein. Adv Immun 1983; 34: 141-212[Medline]. |
| 2. |
Danesh J, Collins R, Appleby P, Peto R.
Fibrinogen, C-reactive protein, albumin or white cell count: meta-analyses of prospective studies of coronary heart disease.
JAMA
1998;
279:
1477-1482 |
| 3. |
Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Braunwald E.
Long-term effects of pravastatin on plasma concentration of C-reactive protein.
Circulation
1999;
100:
230-235 |
| 4. |
Wilkins J, Gallimore JR, Moore EG, Pepys MB.
Rapid automated high sensitivity enzyme immunoassay of C-reactive protein.
Clin Chem
1998;
44:
1358-1361 |
| 5. |
Wilkins J, Gallimore JR, Tennent GA, Hawkins PN, Limburg PC, van Rijswijk MH, et al.
Rapid automated enzyme immunoassay of serum amyloid A.
Clin Chem
1994;
40:
1284-1290 |
| 6. |
Ross R.
Atherosclerosis an inflammatory disease.
N Engl J Med
1999;
340:
115-121 |
| 7. |
Lagrand WK, Visser CA, Hermens W, Niessen WH, Verheugt FW, Wolbink GJ, et al.
C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?
Circulation
1999;
100:
96-102 |
| 8. | Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-436[CrossRef][Medline]. |
| 9. |
Danesh J.
Smouldering arteries? Low-grade inflammation and coronary heart disease.
JAMA
1999;
282:
2169-2171 |
| 10. |
Gabay C, Kushner I.
Acute-phase proteins and other systemic responses to inflammation.
N Engl J Med
1999;
340:
448-455 |
| 11. | Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British regional heart study: cardiovascular risk factors in middle-aged men in 24 towns. BMJ 1981; 283: 179-186. |
| 12. | Phillips A, Shaper AG, Whincup PH. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet 1989; ii: 1434-1436. |
| 13. |
Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG.
Leukocyte count and risk of coronary heart disease.
Am J Epidemiol
1992;
136:
59-70 |
| 14. | Poole S, Walker D, Gaines Das RE, Gallimore JR, Pepys MB. The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study. J Immunol Methods 1998; 214: 1-10[CrossRef][Medline]. |
| 15. | Wong Y-K, Sueur JM, Fall CHD, Orfila J, Ward ME. The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring antibodies against Chlamydia pneumoniae. J Clin Pathol 1999; 2: 99-103. |
| 16. |
Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, et al.
Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies.
Am J Epidemiol
1999;
150:
341-353 |
| 17. | Lowe GDO, Rumely A, Sweetnam PM, Yarnell JWG. Fibrin D-dimer, C-reactive protein and risk of ischaemic heart disease: the Speedwell study. Blood Coagul Fibrin 1999; 10 (suppl 1): S92-S93. |
| 18. | Agewall S, Wikstrand J, Fagerberg B. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men. J Hypertension 1998; 16: 537-541[CrossRef][Medline]. |
| 19. |
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH.
Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.
Circulation
1998;
98:
731-733 |
| 20. | Witherell HL, Smith KL, Ley C, Freidman GD, Orentreich N, Vogelman JH. Helicobacter pylori infection, C-reactive protein, and risk for myocardial infarction: a prospective study. Gastroenterology 1999; 116: A355. |
| 21. | Roivainen M, Viik-Kajarnder M, Palosuo T, Sacks F, Braunwald E. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000; 101: 257. |
| 22. |
Ridker PM, Rifai N, Pfeffer MA, Toivanen P, Leinonen M, Saikku P, et al.
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels.
Circulation
1998;
98:
839-844 |
| 23. |
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
New Engl J Med
1997;
336:
973-979 |
| 24. |
Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al.
C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA-Augsburg cohort study, 1984-1992.
Circulation
1999;
99:
237-242 |
| 25. |
Kuller LH, Tracy RP, Shaten J, Meilahn EN.
Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study.
Am J Epidemiol
1996;
144:
537-547 |
| 26. |
Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al.
Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the cardiovascular health study and the rural health promotion project.
Arterioscler Thromb Vasc Biol
1997;
17:
1121-1127 |
| 27. |
Toss H, Lindahl B, Siegbahn A, Wallentin L.
Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease.
Circulation
1997;
96:
4204-4210 |
| 28. | Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-466[CrossRef][Medline]. |
| 29. | Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999; 145: 375-379[CrossRef][Medline]. |
| 30. |
Cermak JC, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM.
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.
Blood
1993;
82:
513-520 |
| 31. |
de Beer FC, Soutar AK, Baltz ML, Trayner I, Feinstein A, Pepys MB.
Low density and very low density lipoproteins are selectively bound by aggregated C-reactive protein.
J Exp Med
1982;
156:
230-242 |
| 32. |
Bhakdi S, Torzewski M, Klouche M, Hemmes M.
Complement activation and atherogenesis. Binding of CRP to degraded, nonoxidised LDL enhances complement activation.
Arterioscler Thromb Vasc Biol
1999;
19:
2348-2354 |
| 33. |
Cushman M, Legault C, Barrett-Connor EL, Stefanick ML, Kessler C, Judd HL, et al.
Effect of postmenopausal hormones on inflammation-sensitive proteins: the postmenopausal estrogen/ progestin interventions (PEPI) study.
Circulation
1999;
100:
717-722 |
| 34. |
Ridker PM, Hennekens CH, Buring JE, Rifai N.
C reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
N Engl J Med
2000;
342:
836-843 |
(Accepted 22 February 2000)
Read all Rapid Responses